HEPION PHARMACEUTICALS, INC. Increase Decrease In Operating Lease Liability
HEPION PHARMACEUTICALS, INC. (HEPA) reported Increase Decrease In Operating Lease Liability of -$209.02 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-03-12
- HEPION PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2024-12-31 was -$117.95K.
- HEPION PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2024-09-30 was -$36.14K.
- HEPION PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2024-06-30 was -$21.18K.
- HEPION PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2024-03-31 was -$33.75K.
- HEPION PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2024 was -$209.02K.
- HEPION PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2023 was -$96.71K.
- HEPION PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2022 was -$263.38K.
- HEPION PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2021 was -$258.59K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$117.95K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$154.09K derived: sum of 2 quarters · filed 2026-03-12 | -$175.27K derived: sum of 3 quarters · filed 2026-03-12 | -$209.02K 10-K · filed 2026-03-12 |
| 2024-09-30 | -$36.14K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$57.32K derived: sum of 2 quarters · filed 2025-11-12 | -$91.07K 10-Q · filed 2025-11-12 | -$133.20K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$21.18K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$54.93K 10-Q · filed 2025-08-14 | -$97.06K derived: sum of 3 quarters · filed 2025-08-14 | -$98.03K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$33.75K 10-Q · filed 2025-05-19 | -$75.89K derived: sum of 2 quarters · filed 2025-05-19 | -$76.85K derived: sum of 3 quarters · filed 2025-05-19 | -$76.85K derived: sum of 4 quarters · filed 2025-05-19 |
| 2023-12-31 | -$42.13K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-08 | -$43.10K derived: sum of 2 quarters · filed 2025-04-08 | -$43.10K derived: sum of 3 quarters · filed 2025-04-08 | -$96.71K 10-K · filed 2025-04-08 |
| 2023-09-30 | -$964.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$964.00 derived: sum of 2 quarters · filed 2024-11-14 | -$54.58K 10-Q · filed 2024-11-14 | -$106.54K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$53.61K 10-Q · filed 2024-08-13 | -$105.58K derived: sum of 3 quarters · filed 2024-08-13 | -$176.86K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$53.61K 10-Q · filed 2024-05-21 | -$105.58K derived: sum of 2 quarters · filed 2024-05-21 | -$176.86K derived: sum of 3 quarters · filed 2024-05-21 | -$247.34K derived: sum of 4 quarters · filed 2024-05-21 |
| 2022-12-31 | -$51.96K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | -$123.24K derived: sum of 2 quarters · filed 2024-04-16 | -$193.73K derived: sum of 3 quarters · filed 2024-04-16 | -$263.38K 10-K · filed 2024-04-16 |
| 2022-09-30 | -$71.28K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-20 | -$141.76K derived: sum of 2 quarters · filed 2023-11-20 | -$211.41K 10-Q · filed 2023-11-20 | -$278.84K derived: sum of 4 quarters · filed 2023-11-20 |
| 2022-06-30 | -$70.48K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$140.14K 10-Q · filed 2023-08-14 | -$207.56K derived: sum of 3 quarters · filed 2023-08-14 | -$276.01K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$69.65K 10-Q · filed 2023-05-12 | -$137.07K derived: sum of 2 quarters · filed 2023-05-12 | -$205.53K derived: sum of 3 quarters · filed 2023-05-12 | -$328.24K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | -$67.42K derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-10 | -$135.88K derived: sum of 2 quarters · filed 2023-04-10 | -$258.59K derived: sum of 3 quarters · filed 2023-04-10 | -$258.59K 10-K · filed 2023-04-10 |
| 2021-09-30 | -$68.46K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$191.17K derived: sum of 2 quarters · filed 2022-11-14 | -$191.17K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | -$122.71K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$122.71K 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | -$231.87K 10-K · filed 2022-04-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |